Carmegliptin

Carmegliptin (RO-4876904) is an orally active, potent and long-acting dipeptidyl peptidase IV inhibitor. Carmegliptin is also a substrate of P-glycoprotein that synergizes with Verapamil (HY-14275) . Carmegliptin improves insulin sensitivity and reduces hepatic glucose production in hyperglycemic mice. Carmegliptin is promising for research of type 2 diabetes, hypertension and cardiovascular disease[1][2].

Product Specifications

CAS Number

[813452-18-5]

Product Name Alternative

RO-4876904

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Dipeptidyl Peptidase; P-glycoprotein

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/carmegliptin.html

Smiles

O=C(C1)N(C[C@H]1CF)[C@H]2CN3CCC4=CC(OC)=C(OC)C=C4[C@@]([H])3C[C@@H]2N

Molecular Formula

C20H28FN3O3

Molecular Weight

377.45

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Mattei P, et al. Discovery of carmegliptin: a potent and long-acting dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorg Med Chem Lett. 2010 Feb 1;20 (3) :1109-13. |[2]Kuhlmann O, et al. Interaction potential of Carmegliptin with P-glycoprotein (Pgp) transporter in healthy volunteers. J Drug Assess. 2014 Mar 3;3 (1) :28-37.